Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.55 |
| ▸ | NOS1 | P29475 | 4/20 | 0.53 |
| ▸ | AXL | P30530 | 2/20 | 0.53 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | DHPS | P49366 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370496 | 1.00 | IDO1 (0.55) | IDO1NOS1AXLMETAP2ROCK2 | |
| Hydrochloric Acid SCHEMBL632116 | 0.98 | IDO1 (0.53) | IDO1NOS1AXLMETAP2ROCK2 | |
| Hydrochloric Acid SCHEMBL29954979 | 0.98 | IDO1 (0.53) | IDO1NOS1AXLMETAP2ROCK2 | |
| SCHEMBL8784 | 0.77 | IDO1 (0.41) | IDO1NOS1AXLMETAP2ROCK2 | |
| SCHEMBL31178789 | 0.76 | IDO1 (0.56) | IDO1NOS1AXLMETAP2ROCK2 | |
| SCHEMBL15288440 | 0.76 | ROCK1 (0.41) | IDO1NOS1AXLMETAP2ROCK2 | |
| SCHEMBL29951352 | 0.76 | ROCK1 (0.41) | IDO1NOS1AXLMETAP2ROCK2 | |
| SCHEMBL29955211 | 0.76 | IDO1 (0.56) | IDO1NOS1AXLMETAP2ROCK2 | |
| SCHEMBL29956165 | 0.74 | IDO1 (0.35) | IDO1NOS1AXLMETAP2ROCK2 | |
| SCHEMBL21636438 | 0.74 | METAP2 (0.53) | IDO1METAP2NPC1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11495769-B2 | Inorganic light emitting diode and inorganic light emitting device including the same | LG DISPLAY CO., LTD. (KR) | 2022-11-08 | — | — | US | claimed |
| US-20210167321-A1 | INORGANIC LIGHT EMITTING DIODE AND INORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2021-06-03 | — | — | US | claimed |
| US-9980668-B2 | Photoluminescent nanostructure-based sensors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-05-29 | — | — | US | claimed |
| EP-2739977-A1 | PHOTOLUMINESCENT NANOSTRUCTURE-BASED SENSORS | Massachusetts Institute of Technology (US) | 2014-06-11 | — | — | EP | claimed |
| US-20130035567-A1 | PHOTOLUMINESCENT NANOSTRUCTURE-BASED SENSORS | NATIONAL SCIENCE FOUNDATION | 2013-02-07 | — | — | US | claimed |
| WO-2013019722-A1 | PHOTOLUMINESCENT NANOSTRUCTURE-BASED SENSORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-02-07 | — | — | WO | claimed |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-12570607-B2 | Compound as cyclin-dependent kinase 9 inhibitor and use thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2026-03-10 | — | — | US | disclosed |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4688788-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2026-01-15 | — | — | US | disclosed |
| US-12516059-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1745033-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-12-15 | — | — | US | disclosed |
| WO-2005110416-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-1565452-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004043925-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINED AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | IDO1 3942/4885NOS1 4767/4885AXL 4394/4885 |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C3AR1, C5AR1 | IDO1 349/4885NOS1 2770/4885AXL 464/4885 |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | IDO1 4446/4885NOS1 2727/4885AXL 4415/4885 |
| US-12570607-B2 | Compound as cyclin-dependent kinase 9 inhibitor and use thereof | CDK9, CDK4, CDKL4 | IDO1 3551/4885NOS1 3832/4885AXL 1256/4885 |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | IDO1 950/4885NOS1 1797/4885AXL 3835/4885 |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | WRN, MSH2, MSH6 | IDO1 2631/4885NOS1 4535/4885AXL 4741/4885 |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | C3AR1, C5AR1, C5AR2 | IDO1 253/4885NOS1 2585/4885AXL 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.